Background: Trigeminal neuralgia (TN) is a debilitating neuropathic pain disorder often inadequately controlled with oral medications. Botulinum toxin type A (BoNT-A) has emerged as a potential therapeutic option either as monotherapy or in combination with standard pharmacotherapy. Objective: To compare the efficacy and safety of BoNT-A therapy with and without concomitant oral medication in patients with TN. Methods: This single-center, interventional case–control study was conducted on sixty patients with classical or idiopathic TN were randomized into two groups: Group A (n=30) received BoNT-A injections plus oral medication, and Group B (n=30) received BoNT-A injections alone. Patients were assessed at baseline, 14, 30, and 90 days using the Visual Analog Scale (VAS) and daily pain attack frequency. Safety and tolerability measures were recorded.

Trigeminal neuralgia, botulinum toxin type A, neuropathic pain, oral medication, Visual Analog Scale.